Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Moxifloxacin vs. Polytrim for Conjunctivitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by University of Rochester.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00581542
First received: December 18, 2007
Last updated: August 11, 2011
Last verified: August 2011
  Purpose

The purpose of the study is to compare the effect of Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution in treating your child's pink eye. Both these medications are approved by the Food and Drug Administration, for treatment of conjunctivitis. This study will investigate if both of the medications are equally good.


Condition Intervention Phase
Conjunctivitis
Drug: moxifloxacin
Drug: polytrim
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.

Resource links provided by NLM:


Further study details as provided by University of Rochester:

Primary Outcome Measures:
  • Clinical Cure [ Time Frame: 10 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Microbiological cure [ Time Frame: 10 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: March 2007
Estimated Study Completion Date: March 2012
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: moxifloxacin
1-2 drops three times a day for 8-10 days.
Active Comparator: 2 Drug: polytrim
1-2 drops four times a day for 8-10 days.

  Eligibility

Ages Eligible for Study:   1 Year to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1 - 18 years of age with presumed bacterial conjunctivitis.

Exclusion Criteria:

  • Previous antibiotics or to receive systemic antibiotic.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00581542

Contacts
Contact: Francis Gigliotti, MD 585-275-5944 Francis_gigliotti@urmc.rochester.edu
Contact: Barbra L Murante, RN 585-275-1549 Barbra_murante@urmc.rochester.edu

Locations
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Francis Gigliotti, MD University of Rochester
  More Information

No publications provided

Responsible Party: Francis Gigliotti, MD, University of Rochester
ClinicalTrials.gov Identifier: NCT00581542     History of Changes
Other Study ID Numbers: RSRB #17454
Study First Received: December 18, 2007
Last Updated: August 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ophthalmic Solutions
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmaceutical Solutions
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on November 23, 2014